24.15
0.41 (1.73%)
| Penutupan Terdahulu | 23.74 |
| Buka | 22.86 |
| Jumlah Dagangan | 5,139 |
| Purata Dagangan (3B) | 50,907 |
| Modal Pasaran | 1,059,972,480 |
| Harga / Pendapatan (P/E TTM) | 483.00 |
| Harga / Jualan (P/S) | 198.41 |
| Harga / Buku (P/B) | 94.46 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Apr 2025 |
| Margin Keuntungan | 28.99% |
| Margin Operasi (TTM) | -68.64% |
| EPS Cair (TTM) | 0.050 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -36.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 136.50% |
| Nisbah Semasa (MRQ) | 10.71 |
| Aliran Tunai Operasi (OCF TTM) | 2.08 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.27 M |
| Pulangan Atas Aset (ROA TTM) | 7.18% |
| Pulangan Atas Ekuiti (ROE TTM) | 14.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Menaik | Bercampur |
| Medical Instruments & Supplies (Global) | Bercampur | Menurun | |
| Stok | Anbio Biotechnology | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 2.00 |
|
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.78% |
| % Dimiliki oleh Institusi | 4.94% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |